8-K: Aclarion, Inc. Amends Equity Line Purchase Agreement with White Lion Capital, Extending Term and Adding New Pricing Options

Aclarion, Inc. has amended its equity line purchase agreement with White Lion Capital, extending the agreement's term to December 31, 2025, and introducing two new methods for pricing share sales.

Summary

• Aclarion, Inc. (the 'Company') and White Lion Capital, LLC ('White Lion') have amended their existing Equity Line Purchase Agreement.
• The amendment extends the agreement's expiration date from December 31, 2024, to December 31, 2025.
• It introduces two new methods for pricing shares sold under the agreement: Accelerated Purchase Notice and Pre-Market Purchase Notice.
• The Company has already issued shares to White Lion for total proceeds of $3,216,981, leaving approximately $6.8 million available under the agreement.
• In consideration for White Lion's commitments, Aclarion has issued 560,915 shares of Common Stock to White Lion.
• The amendment is subject to stockholder approval as required by Nasdaq listing rules.

Sentiment

Score: 4

Explanation: The amendment provides Aclarion with continued access to capital, which is positive. However, the dilutive nature of the agreement, the discounted pricing, and the need for stockholder approval introduce negative elements. Overall, the sentiment is slightly negative due to concerns about the company's ability to raise capital under more favorable terms.

Positives

• The extension of the agreement provides Aclarion with continued access to capital through December 31, 2025.
• The new pricing options offer Aclarion greater flexibility in managing its capital needs.
• The agreement allows Aclarion to raise capital on an as-needed basis, potentially minimizing dilution.

Negatives

• The issuance of 560,915 shares to White Lion as commitment shares results in immediate dilution for existing shareholders.
• The pricing mechanisms under the agreement involve discounts to the market price, which could negatively impact the share price.
• The reliance on equity financing may signal a lack of alternative funding options or underlying financial weakness.

Risks

• The company's stock price may decline, making it more expensive to raise capital under the agreement.
• White Lion may be unwilling or unable to purchase shares when requested by the company.
• Market conditions may make it difficult for the company to sell shares at favorable prices.
• The company may not be able to meet the conditions required to utilize the equity line.
• The agreement is subject to stockholder approval, which may not be obtained.

Future Outlook

The company has secured access to potential funding through the end of 2025, subject to market conditions and other factors. The new pricing mechanisms provide flexibility, but the company's ability to utilize the equity line effectively will depend on its operational performance and investor sentiment.

Management Comments

• By:/s/ John Lorbiecki Name: John Lorbiecki Title: Chief Financial Officer

Industry Context

This amendment reflects a common strategy for companies, particularly in the growth or development stage, to secure access to capital. Equity lines provide a flexible, albeit potentially dilutive, way to raise funds as needed. This is particularly relevant in industries with high capital requirements or volatile market conditions.

Comparison to Industry Standards

• The use of equity line purchase agreements is a common practice among publicly traded companies, especially those in the small to mid-cap range.
• Other companies in the medical technology sector, such as Natus Medical Incorporated and Masimo Corporation, have utilized similar financing arrangements in the past.
• The terms of Aclarion's agreement, including the pricing discounts and commitment shares, are generally in line with industry standards for these types of agreements.
• However, the specific terms can vary widely depending on the company's financial condition, market capitalization, and negotiating leverage.

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution due to the issuance of new shares.
• Employees: The agreement may provide the company with the capital needed to continue operations and fund growth, potentially impacting job security and opportunities.
• Customers: The impact on customers is likely to be minimal in the short term.
• Suppliers: The impact on suppliers is likely to be minimal in the short term.
• Creditors: The agreement may improve the company's ability to meet its financial obligations, which could be positive for creditors.

Next Steps

• The company will seek stockholder approval for the amendment to the Equity Line Purchase Agreement.
• Aclarion may issue additional Purchase Notices to White Lion to raise capital under the agreement.
• The company will continue to monitor market conditions and its capital needs to determine the timing and amount of any future share sales.

Key Dates

Keywords

Aclarion, White Lion Capital, Equity Line Purchase Agreement, Common Stock, Capital Raise, Dilution, Accelerated Purchase Notice, Pre-Market Purchase Notice, VWAP, Nasdaq, Amendment, Commitment Shares